The remainder comprised 45 people whose tumour records showed no evidence of dMMR testing, 74 with MMR proficient tumours, 53 with MLH1 deficiency/MSI-High status but no evidence of downstream somatic testing, and eight with MLH1 deficiency but mutant BRAF/MLH1 promoter hypermethylation. This evidence concerns the gene MLH1 and neoplasm.